Assess whether RWE can replace or only supplement an RCT (e1d653)

Situation

RWE evidence-strategy director owns RWE can replace or inside an RWE group proposing a post-marketing study instead of a new RCT with 505(b)(2) literature-to-product bridge table as the only packet. A pediatric ethicist objecting to the proposed design is what changed the clock for this Pharma & Life Sciences Pharmacovigilance file.

Decision

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose RWE can replace / Only supplement an RCT using 505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• Authorize RWE can replace now; 505(b)(2) literature-to-product bridge table already has the discriminator after a pediatric ethicist objecting to the proposed design.
• Keep Only supplement an RCT in force until 505(b)(2) literature-to-product bridge table is completed after a pediatric ethicist objecting to the proposed design for RWE evidence-strategy director.
• Treat 505(b)(2) literature-to-product bridge table as RWE can replace because both readings appear after a pediatric ethicist objecting to the proposed design.
• Refuse a Pharma & Life Sciences close: RWE evidence-strategy director does not have the page RWE can replace or turns on in 505(b)(2) literature-to-product bridge table.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim RWE evidence-strategy director would keep.
• For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against a pediatric ethicist objecting to the proposed design and write the one fact that would move RWE can replace or for RWE evidence-strategy director.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Pharmacovigilance packet (505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design). The follow-on Pharmacovigilance action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.